Metabolic reprogramming of clear cell renal cell carcinoma.
cancer
ccRCC
glucose
lipids
lipids ccRCC
metabolism
metabolism reprogramming
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
03
2023
accepted:
16
05
2023
medline:
26
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
Clear cell renal cell carcinoma (ccRCC) is a malignancy that exhibits metabolic reprogramming as a result of genetic mutations. This reprogramming accommodates the energy and anabolic needs of the cancer cells, leading to changes in glucose, lipid, and bio-oxidative metabolism, and in some cases, the amino acid metabolism. Recent evidence suggests that ccRCC may be classified as a metabolic disease. The metabolic alterations provide potential targets for novel therapeutic interventions or biomarkers for monitoring tumor growth and prognosis. This literature review summarized recent discoveries of metabolic alterations in ccRCC, including changes in glucose, lipid, and amino acid metabolism. The development of metabolic drugs targeting these metabolic pathways was also discussed, such as HIF-2α inhibitors, fatty acid synthase (FAS) inhibitors, glutaminase (GLS) inhibitors, indoleamine 2,3-dioxygenase (IDO) inhibitors, and arginine depletion. Future trends in drug development are proposed, including the use of combination therapies and personalized medicine approaches. In conclusion, this review provides a comprehensive overview of the metabolic alterations in ccRCC and highlights the potential for developing new treatments for this disease.
Identifiants
pubmed: 37347113
doi: 10.3389/fendo.2023.1195500
pmc: PMC10280292
doi:
Substances chimiques
Lipids
0
Amino Acids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1195500Informations de copyright
Copyright © 2023 Zhu, Wang, Lu and Ou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunother Cancer. 2018 Jun 20;6(1):61
pubmed: 29921320
Oncotarget. 2016 Oct 11;7(41):66540-66557
pubmed: 27572319
Ann Oncol. 2018 Jun 1;29(6):1402-1408
pubmed: 29659672
Nat Med. 2021 May;27(5):802-805
pubmed: 33888901
Eur Urol. 2016 Apr;69(4):646-657
pubmed: 26298207
J Clin Invest. 2021 Feb 15;131(4):
pubmed: 33320840
Int J Cancer. 2010 Jun 15;126(12):2762-72
pubmed: 20104527
Eur Urol. 2019 May;75(5):752-763
pubmed: 30293904
J Ovarian Res. 2021 Oct 22;14(1):140
pubmed: 34686201
Int J Biochem Mol Biol. 2011;2(1):8-23
pubmed: 21494411
Cancer Metastasis Rev. 2022 Mar;41(1):17-31
pubmed: 34741716
Nat Rev Mol Cell Biol. 2019 Jul;20(7):436-450
pubmed: 30976106
Biochem J. 2009 Feb 15;418(1):29-37
pubmed: 18937644
Nat Commun. 2017 Nov 24;8(1):1769
pubmed: 29176561
Pharmacol Res. 2019 Dec;150:104511
pubmed: 31678210
Oncotarget. 2017 Apr 25;8(33):54548-54557
pubmed: 28903363
Nat Rev Nephrol. 2017 Jul;13(7):410-419
pubmed: 28480903
Cancer Cell. 2016 Jan 11;29(1):104-116
pubmed: 26766592
Cancer Res. 2009 Oct 15;69(20):7986-93
pubmed: 19826036
PLoS Biol. 2003 Dec;1(3):E83
pubmed: 14691554
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cells. 2019 Mar 03;8(3):
pubmed: 30832409
Nat Commun. 2019 Apr 8;10(1):1617
pubmed: 30962421
Cell. 2022 Jul 21;185(15):2678-2689
pubmed: 35839759
Cell Metab. 2022 Mar 1;34(3):355-377
pubmed: 35123658
Annu Rev Cell Dev Biol. 2011;27:441-64
pubmed: 21985671
J Clin Oncol. 2018 Oct 29;:JCO2018792549
pubmed: 30372397
Cell Metab. 2020 Feb 4;31(2):267-283.e12
pubmed: 31866442
Biochem J. 1998 Nov 15;336 ( Pt 1):1-17
pubmed: 9806879
Expert Opin Drug Discov. 2016 Dec;11(12):1187-1199
pubmed: 27701891
J Clin Oncol. 2018 Mar 20;36(9):867-874
pubmed: 29257710
Nature. 2016 Nov 3;539(7627):112-117
pubmed: 27595394
Mol Cell. 2008 May 23;30(4):393-402
pubmed: 18498744
Adv Exp Med Biol. 2014;772:205-27
pubmed: 24272361
J Biol Chem. 2017 Oct 13;292(41):16825-16832
pubmed: 28842498
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
Nat Rev Cancer. 2011 Dec 15;12(1):9-22
pubmed: 22169972
Biochem J. 2000 Jun 1;348 Pt 2:257-61
pubmed: 10816417
Oncologist. 2011;16(4):432-44
pubmed: 21441297
J Cell Sci. 2016 Sep 15;129(18):3367-73
pubmed: 27635066
Clin Cancer Res. 2020 Feb 15;26(4):793-803
pubmed: 31727677
Life Sci. 2022 Nov 1;308:120922
pubmed: 36058262
Compr Physiol. 2014 Jan;4(1):177-97
pubmed: 24692138
J Immunol. 2020 Aug 15;205(4):1009-1023
pubmed: 32690659
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35288468
CA Cancer J Clin. 2017 Nov;67(6):507-524
pubmed: 28961310
Autophagy. 2021 Sep;17(9):2054-2081
pubmed: 32804006
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Exp Mol Med. 2016 Mar 11;48:e218
pubmed: 26964834
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188559
pubmed: 33965513
Science. 2020 Apr 10;368(6487):
pubmed: 32273439
N Engl J Med. 2021 Nov 25;385(22):2036-2046
pubmed: 34818478
J Am Soc Nephrol. 2016 Aug;27(8):2227-37
pubmed: 26961346
Int J Mol Sci. 2015 Jan 02;16(1):924-49
pubmed: 25561239
Cancer Cell. 2020 Dec 14;38(6):803-817.e4
pubmed: 33157048
Clin Cancer Res. 2013 Aug 15;19(16):4309-14
pubmed: 23719265
J Lipid Res. 1987 Oct;28(10):1177-84
pubmed: 3681141
Cell Rep. 2015 Jul 7;12(1):116-127
pubmed: 26119730
J Med Chem. 2019 Aug 8;62(15):6876-6893
pubmed: 31282155
Clin Cancer Res. 2019 Jun 1;25(11):3220-3228
pubmed: 30770348
J Clin Invest. 2013 Sep;123(9):3678-84
pubmed: 23999442
Biosci Rep. 2016 Nov 29;36(6):
pubmed: 27707936
Cell Res. 2018 Mar;28(3):265-280
pubmed: 29219147
Nature. 2015 Nov 12;527(7577):186-91
pubmed: 26466563
Protein Cell. 2014;5(8):592-602
pubmed: 25015087
Biochem Soc Trans. 2001 May;29(Pt 2):250-67
pubmed: 11356164
Nat Rev Mol Cell Biol. 2020 May;21(5):268-283
pubmed: 32144406
Trends Biochem Sci. 2010 Aug;35(8):427-33
pubmed: 20570523
Int J Mol Sci. 2019 Dec 25;21(1):
pubmed: 31881671
J Clin Invest. 2019 Feb 1;129(2):442-451
pubmed: 30614813
Drug Discov Today. 2019 Dec;24(12):2332-2340
pubmed: 31541711
Curr Opin Chem Biol. 2010 Jun;14(3):331-40
pubmed: 20395165
Postepy Biochem. 2019 Jun 06;65(2):95-102
pubmed: 31642647
J Urol. 2008 Aug;180(2):729-36
pubmed: 18555493
Cancer Res. 2015 Jun 15;75(12):2541-52
pubmed: 25952651
Dis Markers. 2022 Feb 27;2022:1452861
pubmed: 35265223
J Urol. 2008 Sep;180(3):1137-40
pubmed: 18639282
FEBS Open Bio. 2019 Jan 07;9(2):241-247
pubmed: 30761250
Cell Death Dis. 2019 May 28;10(6):416
pubmed: 31138790
Cell Metab. 2018 Feb 6;27(2):281-298
pubmed: 29129785
Cancer Treat Rev. 2015 Nov;41(9):767-76
pubmed: 26169313
Cancer Discov. 2019 Aug;9(8):1006-1021
pubmed: 31088840
Lancet Oncol. 2022 Jul;23(7):888-898
pubmed: 35688173
Br J Cancer. 2021 Apr;124(9):1533-1539
pubmed: 33674736
Cancers (Basel). 2020 Apr 30;12(5):
pubmed: 32365833
Sci Rep. 2016 Jun 30;6:28932
pubmed: 27357243
Semin Nephrol. 2020 Jan;40(1):2-13
pubmed: 32130963
Oncotarget. 2018 Jun 1;9(42):26868-26883
pubmed: 29928490
Nat Chem Biol. 2017 Jan;13(1):81-90
pubmed: 27842066
Nat Rev Drug Discov. 2019 May;18(5):379-401
pubmed: 30760888
Oncotarget. 2016 Jun 21;7(25):37762-37772
pubmed: 27192116
Clin Cancer Res. 2015 Jun 1;21(11):2480-6
pubmed: 25739672
EClinicalMedicine. 2021 Mar 30;34:100797
pubmed: 33870151
Science. 2001 Apr 20;292(5516):468-72
pubmed: 11292861
Mol Cell Proteomics. 2009 May;8(5):971-85
pubmed: 19164279
Front Oncol. 2022 Jul 11;12:899987
pubmed: 35898882
J Clin Invest. 2013 Sep;123(9):3664-71
pubmed: 23999440
Carcinogenesis. 2002 May;23(5):759-68
pubmed: 12016148
Cell Metab. 2006 Mar;3(3):177-85
pubmed: 16517405
Cancer Res. 2012 Jul 15;72(14):3471-9
pubmed: 22628425
Nat Med. 2018 Jul;24(7):1036-1046
pubmed: 29892070
Cell Cycle. 2018;17(7):903-916
pubmed: 29633904
Br J Clin Pharmacol. 2019 Aug;85(8):1751-1760
pubmed: 30973970
Clin Cancer Res. 2019 May 1;25(9):2708-2716
pubmed: 30796035
Clin Cancer Res. 2007 Dec 1;13(23):6993-7002
pubmed: 18056175
Nat Rev Cancer. 2016 Sep 23;16(10):663-73
pubmed: 27658636
Nat Chem Biol. 2013 Apr;9(4):271-6
pubmed: 23434853
Curr Opin Immunol. 2021 Jun;70:7-14
pubmed: 33418116
Cell. 2017 Oct 5;171(2):358-371.e9
pubmed: 28985563
Front Cell Dev Biol. 2019 Jan 29;7:4
pubmed: 30761299
PLoS One. 2021 Nov 3;16(11):e0259241
pubmed: 34731180
Nat Rev Nephrol. 2021 Apr;17(4):245-261
pubmed: 33144689
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
Pharmacol Res. 2017 Jun;120:116-132
pubmed: 28330784